Bug or feature?
That’s the crucial question about the enormous variability in the makeup of various batches of the experimental mRNA treatment intended to mitigate the effects of infection with the Wuhan Coronavirus
Many thanks to Hellequin GB for translating this article from AUF1. The translator’s comments are in square brackets:
Chemically surprisingly different “vaccine” batches from BioNTech
A Leipzig professor of analytical chemistry recently found that even the outward appearance of the alleged Corona vaccine from the Mainz-based company BioNTech is surprisingly different from different production dates. More detailed analyses by the expert revealed astonishing things.
The company BioNTech of the married couple Özlem Türeci and Ugur Sahin [Jihadists?] has existed since 2008, but had not brought a product onto the market until the Corona pandemic. When the Mainz-based company from the Goldgrube [street name and seat of the company] launched large quantities of the allegedly technically advanced RNA “vaccine” BNT162b2 onto the market worldwide for billions of people at high speed from the end of 2020 after an amazingly short test phase, experts were amazed at how this might work without quality problems.
Danish study shows extreme differences in effectiveness
And indeed — as Daniel Matissek earlier reported here at AUF1 — a current Danish study shows significant differences in the side effects of the “vaccine” from different production times. These production batches or “lots” must be numbered and clearly documented so that inspectors can determine who made what mistake when and if problems arise.
The Danish researchers found that some batches caused a particularly large number of reports of suspected vaccine damage, others significantly less. Was it sloppy — or was the recipe different at different times? Also striking: Denmark received a certain batch particularly frequently — was one or the other lot delivered with priority after expectations of profit?
Even officially: Chemical composition different
The Leipzig chemistry professor Jörg Matysik and his colleague, the expert in organic chemistry Prof. Gerald Dyker from Bochum, researched with other scientists about the production circumstances of the BioNTech miracle drug. Grotesque: Officially, the recipe for producing the “vaccine” is not clear. The fat globules (nanoparticles) that smuggle the RNA into the patient’s cells can be amazingly different in size. The pH value, which indicates how acidic a solution is, may also vary by a full unit — only a tenth of a unit is usual! The substance ALC-0315, from which the nanoparticles are partly made, may also be contained in different proportions. In addition: The safety data sheet of ALC-0315 states that the substance is carcinogenic and irritating to the skin. After Matysik’s request, the information was described as incorrect and deleted.
Dyker and Matysik asked the Paul Ehrlich Institute (PEI) in Berlin, which is responsible for approvals in Germany, why the tolerances for the BioNTech “vaccine” were so high — no answer.